<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30195239</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>10</Month>            <Day>22</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>22</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1768-3254</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>157</Volume>                    <PubDate>                        <Year>2018</Year>                        <Month>Sep</Month>                        <Day>05</Day>                    </PubDate>                </JournalIssue>                <Title>European journal of medicinal chemistry</Title>                <ISOAbbreviation>Eur J Med Chem</ISOAbbreviation>            </Journal>            <ArticleTitle>Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.</ArticleTitle>            <Pagination>                <MedlinePgn>1292-1299</MedlinePgn>            </Pagination>            <ELocationID EIdType="pii" ValidYN="Y">S0223-5234(18)30737-2</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejmech.2018.08.065</ELocationID>            <Abstract>                <AbstractText>Modification of platinum (II) into lipophilic platinum (IV) compounds by introducing biologically active molecules were widely employed to develop new platinum-based prodrugs in the past decade. In this paper, two chlorambucil platinum (IV) complexes, CLB-Pt and CLB-Pt-CLB, were synthesized and displayed very potent antiproliferative activity against all the tested cancer cell lines, such as A549, HeLa and MCF-7, especially to treat the well-known refractory triple-negative breast cancer. CLB-Pt-CLB significantly improved cell-killing effect in triple-negative subtype MDA-MB-231 cells, and showed much stronger cytotoxicity than either monotherapy or combination of cisplatin and chlorambucil. CLB-Pt-CLB prodrug entered cells in dramatically increased amount compared with cisplatin and enhanced DNA damage, inducing cancer cell apoptosis. It exhibited high anticancer activity and no observable toxicity in BALB/c nude mice bearing MDA-MB-231 tumors. The chlorambucil moiety not only greatly assisted the passive diffusion of CLB-Pt-CLB into cells, but also produced the synergism with cisplatin in targeting DNA.</AbstractText>                <CopyrightInformation>Copyright © 2018 Elsevier Masson SAS. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Ma</LastName>                    <ForeName>Zhong-Ying</ForeName>                    <Initials>ZY</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Chemical Biology, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wang</LastName>                    <ForeName>Dong-Bo</ForeName>                    <Initials>DB</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Chemical Biology, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Song</LastName>                    <ForeName>Xue-Qing</ForeName>                    <Initials>XQ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Chemical Biology, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wu</LastName>                    <ForeName>Yi-Gang</ForeName>                    <Initials>YG</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Chemical Biology, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chen</LastName>                    <ForeName>Qian</ForeName>                    <Initials>Q</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Chemical Biology, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zhao</LastName>                    <ForeName>Chun-Lai</ForeName>                    <Initials>CL</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Chemical Biology, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Jing-Yi</ForeName>                    <Initials>JY</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Chemical Biology, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Cheng</LastName>                    <ForeName>Shi-Hao</ForeName>                    <Initials>SH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Chemical Biology, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Xu</LastName>                    <ForeName>Jing-Yuan</ForeName>                    <Initials>JY</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Chemical Biology, Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics (Theranostics), School of Pharmacy, Tianjin Medical University, Tianjin, 300070, China. Electronic address: xujingyuan@tmu.edu.cn.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>08</Month>                <Day>27</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>France</Country>            <MedlineTA>Eur J Med Chem</MedlineTA>            <NlmUniqueID>0420510</NlmUniqueID>            <ISSNLinking>0223-5234</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D009944">Organoplatinum Compounds</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D011355">Prodrugs</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>18D0SL7309</RegistryNumber>                <NameOfSubstance UI="D002699">Chlorambucil</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName>                <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D002699" MajorTopicYN="N">Chlorambucil</DescriptorName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D004354" MajorTopicYN="N">Drug Screening Assays, Antitumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D009944" MajorTopicYN="N">Organoplatinum Compounds</DescriptorName>                <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D011355" MajorTopicYN="N">Prodrugs</DescriptorName>                <QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName>                <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D014945" MajorTopicYN="N">Wound Healing</DescriptorName>                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Chlorambucil</Keyword>            <Keyword MajorTopicYN="N">Cisplatin</Keyword>            <Keyword MajorTopicYN="N">Decreased toxicity</Keyword>            <Keyword MajorTopicYN="N">Platinum(IV) prodrugs</Keyword>            <Keyword MajorTopicYN="N">Synergistic effects</Keyword>            <Keyword MajorTopicYN="N">Triple-negative breast cancer</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>02</Month>                <Day>01</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>04</Month>                <Day>01</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>08</Month>                <Day>24</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30195239</ArticleId>            <ArticleId IdType="pii">S0223-5234(18)30737-2</ArticleId>            <ArticleId IdType="doi">10.1016/j.ejmech.2018.08.065</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>